GEMMs as preclinical models for testing pancreatic cancer therapies
Pancreatic ductal adenocarcinoma is the most common form of pancreatic tumour, with a very limited survival rate and currently no available disease-modifying treatments. Despite recent advances in the production of genetically engineered mouse models (GEMMs), the development of new therapies for pan...
Main Authors: | Aarthi Gopinathan, Jennifer P. Morton, Duncan I. Jodrell, Owen J. Sansom |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2015-10-01
|
Series: | Disease Models & Mechanisms |
Subjects: | |
Online Access: | http://dmm.biologists.org/content/8/10/1185 |
Similar Items
-
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
by: Sentia eIriana, et al.
Published: (2016-04-01) -
Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model
by: Kavita Mallya, et al.
Published: (2020-09-01) -
Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
by: Natalia Michalak, et al.
Published: (2023-06-01) -
Oral mycobiota and pancreatic ductal adenocarcinoma
by: Ailin Wei, et al.
Published: (2022-12-01) -
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
by: Serena Veschi, et al.
Published: (2018-09-01)